Combination therapy with GLP-1 RAs and thiazolidinediones is associated with a reduced risk for mortality in patients with T2D, a study finds.

Now, researchers at Thomas Jefferson University have found that combining two other diabetes drugs—dapagliflozin and ...

Daniel Drucker, the Canadian scientist renowned for discoveries that sparked the advent of Ozempic and other GLP-1 medicines ...

Dozens of trials testing GLP-1 drugs like semaglutide, the medicine in Ozempic and Wegovy, against a placebo suggest that ...

Originally developed to treat Type 2 diabetes, glucagon-like peptide 1 (GLP-1s) are now being studied to explore their ...

Successful initial administration and full enrollment in first-in-human LIBERATE-1™ study of NPM-115 (exenatide implant) in obese and overweight subjects with top-line data expected in mid-2025 ...

Financing strengthens balance sheet, extending expected runway into the second quarter of 2026 Enables accelerated ...

Together, these data demonstrate the versatility of the NanoPortal technology beyond NPM-115 (exenatide implant) and provide significant encouragement for continued development of each program. The ...

This led to a synthetic equivalent named exenatide, which was granted Food and Drug Administration approval for the treatment of Type 2 diabetes. Although not the first-line treatment, exenatide ...